Moderna has revised its 2025 sales forecast, lowering it by approximately $1 billion. The company now anticipates revenue to range between $1.5 billion and $2.5 billion, with the majority expected in the second half of the year. This adjustment comes as Moderna faces several potential challenges, including increased competition in the Covid vaccine market, where its U.S. retail market share dropped from 48% in 2023 to 40% by the end of 2024. Additionally, overall vaccination rates in the U.S. fell by about 7% in the fall of 2024 compared to the previous year. Despite these headwinds, Moderna plans to reduce its 2025 cash cost expenses by $1 billion and aims for further cost reductions of $500 million in 2026. The company’s shares plummeted 18% in premarket trading following the announcement, with other vaccine stocks like Novavax, BioNTech, and Pfizer also experiencing declines.
Source: www.cnbc.com
